Publications
241 results found
Ellis HC, Moffatt MF, Churchward C, et al., 2023, Molecular assessment of mycobacterial burden in the treatment of nontuberculous mycobacterial disease., ERJ Open Res, Vol: 9, ISSN: 2312-0541
INTRODUCTION: Nontuberculous pulmonary disease causes significant morbidity and mortality. Efforts to tackle infections are hampered by the lack of reliable biomarkers for diagnosis, assessment and prognostication. The aim of this study was to develop molecular assays capable of identifying and quantifying multiple nontuberculous mycobacterial (NTM) species and to examine their utility in following individual patients' clinical courses. METHODS: DNA was extracted from 410 sputum samples obtained longitudinally from a cohort of 38 patients who were commencing treatment for either Mycobacterium abscessus or Mycobacterium avium complex or who were patients with bronchiectasis who had never had positive cultures for mycobacteria. NTM quantification was performed with quantitative PCR assays developed in-house. RESULTS: The molecular assays had high in vitro sensitivity and specificity for the detection and accurate quantification of NTM species. The assays successfully identified NTM DNA from human sputum samples (in vivo sensitivity: 0.86-0.87%; specificity: 0.62-0.95%; area under the curve: 0.74-0.92). A notable association between NTM copy number and treatment (Friedman ANOVA (df)=22.8 (3), p≤0.01 for M. abscessus treatment group) was also demonstrated. CONCLUSION: The quantitative PCR assays developed in this study provide affordable, real-time and rapid measurement of NTM burden, with significant implications for prompt management decisions.
Dhar R, Singh S, Talwar D, et al., 2023, Clinical outcomes of bronchiectasis in India: data from the EMBARC/Respiratory Research Network of India registry, EUROPEAN RESPIRATORY JOURNAL, Vol: 61, ISSN: 0903-1936
van Tonder AJ, Ellis HC, Churchward CP, et al., 2022, Mycobacterium avium complex (MAC) genomics and transmission in a London hospital., Eur Respir J
BACKGROUND: Non-tuberculous mycobacteria are environmental microorganisms and opportunistic pathogens in individuals with pre-existing lung conditions such as cystic fibrosis (CF) and non-CF bronchiectasis (BX). Whilst recent studies of Mycobacterium abscessus have identified transmission within single CF centres as well as nationally and globally, transmission of other NTM species is less well studied. METHODS: To investigate the potential for transmission of the Mycobacterium avium complex (MAC) we sequenced 996 isolates from 354 CF and non-CF patients at the Royal Brompton Hospital (RBH), London (collected 2013-2016), and analysed them in a global context. Epidemiological links were identified from patient records. Previously published genomes were used to characterise global population structures. RESULTS: We identified putative transmission clusters in three MAC species, although few epidemiological links could be identified. For M. avium, lineages were largely limited to single countries, whilst for M. chimaera, global transmission clusters previously associated with heater cooler units (HCUs) were found. However, the immediate ancestor of the lineage causing the major HCU-associated outbreak was a lineage already circulating in patients. CONCLUSIONS: CF and non-CF patients shared transmission chains, although the lack of epidemiological links suggested that most transmission is indirect and may involve environmental intermediates or asymptomatic carriage in the wider population.
Loebinger MR, Quint JK, van der Laan R, et al., 2022, A SYSTEMATIC LITERATURE REVIEW AND METAANALYSIS OF PATIENT RISK FACTORS FOR NONTUBERCULOUS MYCOBACTERIAL PULMONARY DISEASE (NTM-PD), Publisher: BMJ PUBLISHING GROUP, Pages: A84-A85, ISSN: 0040-6376
Loebinger MR, van der Laan R, Obradovic M, et al., 2022, TESTING AT-RISK PATIENTS FOR NTM-PD IN CURRENT CLINICAL PRACTICE: RESULTS OF AN INTERNATIONAL SURVEY, Publisher: BMJ PUBLISHING GROUP, Pages: A83-A84, ISSN: 0040-6376
Kumar K, Cuthbertson L, Ellis HC, et al., 2022, THE LUNG MICROBIOME IN NONTUBERCULOUS MYCOBACTERIAL PULMONARY DISEASE, Publisher: BMJ PUBLISHING GROUP, Pages: A36-A36, ISSN: 0040-6376
Halbeisen FS, Pedersen ESL, Goutaki M, et al., 2022, Lung function from school age to adulthood in primary ciliary dyskinesia, EUROPEAN RESPIRATORY JOURNAL, Vol: 60, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 1
Nwankwo L, Donovan J, Ni M, et al., 2022, Evaluation of remote triazole capillary blood testing to facilitate remote therapeutic drug monitoring (TDM): A validation study, Publisher: OXFORD UNIV PRESS, Pages: 257-259, ISSN: 1369-3786
Shoemark A, Griffin H, Wheway G, et al., 2022, Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in bronchiectasis, EUROPEAN RESPIRATORY JOURNAL, Vol: 60, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 1
Peake S, Jones A, Jose R, et al., 2022, Do adults with Primary Ciliary Dyskinesia (PCD) have a positive experience of home spirometry?, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
Lamb G, Stoll S, Jose R, et al., 2022, Assessment of a self-administered home intravenous antimicrobial therapy service for patients with chronic suppurative lung disease, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
Cheong J, Boreland S, Belkarty B, et al., 2022, Implementing tablet-based ototoxicity screening in adult respiratory patients, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
Hill AT, Grillo L, Gruffydd-Jones K, et al., 2022, British Thoracic Society Quality Standard for Clinically Significant Bronchiectasis in Adults 2022, BMJ OPEN RESPIRATORY RESEARCH, Vol: 9
O'Neill K, Lakshmipathy GR, Neely C, et al., 2022, Multiple-Breath Washout Outcome Measures in Adults with Bronchiectasis, ANNALS OF THE AMERICAN THORACIC SOCIETY, Vol: 19, Pages: 1489-1497, ISSN: 1546-3222
- Author Web Link
- Cite
- Citations: 1
Kumar K, Loebinger MR, 2022, Occupational Exposures in Nontuberculous Mycobacterial Pulmonary Disease Response, CHEST, Vol: 162, Pages: E107-E107, ISSN: 0012-3692
Davies J, Hughes D, Rosenthal M, et al., 2022, An invisible threat? Aspergillus positive cultures and co-infecting bacteria in airway sample, Journal of Cystic Fibrosis, ISSN: 1569-1993
BackgroundAspergillus fumigatus (Af) infection is associated with poor lung health in chronic suppurative lung diseases but often goes undetected. We hypothesised that inhibition of Af growth by Pseudomonas aeruginosa (Pa) increases the frequency of false-negative Af culture in co-infected people. Using a substantial group of cystic fibrosis (CF) airway samples, we assessed the relationship between Af and bacterial pathogens, additionally comparing fungal culture with next-generation sequencing.MethodsFrequency of co-culture was assessed for 44,554 sputum/BAL cultures, from 1,367 CF patients between the years 2010–2020. In a subgroup, Internal Transcribed Spacer-2 (ITS2) fungal sequencing was used to determine sequencing-positive, culture-negative (S+/C-) rates.ResultsPa+ samples were nearly 40% less likely (P<0.0001) than Pa- samples to culture Af, an effect that was also seen with some other Gram-negative isolates. This impact varied with Pa density and appeared to be moderated by Staphylococcus aureus co-infection. Sequencing identified Af-S+/C- for 40.1% of tested sputa. Samples with Pa had higher rates of Af-S+/C- (49.3%) than those without (35.7%; RR 1.38 [1.02–1.93], P<0.05). Af-S+/C- rate was not changed by other common bacterial infections. Pa did not affect the S+/C- rates of Candida, Exophiala or Scedosporium.ConclusionsPa/ Af co-positive cultures are less common than expected in CF. Our findings suggest an Af-positive culture is less likely in the presence of Pa. Interpretation of negative cultures should be cautious, particularly in Pa-positive samples, and a companion molecular diagnostic could be useful. Further work investigating mechanisms, alternative detection techniques and other chronic suppurative lung diseases is needed.
Kumar K, Loebinger MR, Ghafur S, 2022, The role of wirelessly observed therapy in improving treatment adherence., Future Healthc J, Vol: 9, Pages: 179-182, ISSN: 2514-6645
Wirelessly observed therapy (WOT) offers a novel way of monitoring treatment adherence. In this article, we provide an overview of how this technology works and discuss the evidence for its clinical effectiveness in tuberculosis, hepatitis C virus infection, mental health and cardiovascular disease. We consider the acceptability of WOT to patients as well as potential issues relating to patient autonomy and data protection. We highlight the current limited data on its economic impact and reflect on its future role in patient care.
Hull RC, Huang JTJ, Barton AK, et al., 2022, Sputum Proteomics in Nontuberculous Mycobacterial Lung Disease, CHEST, Vol: 161, Pages: 1180-1191, ISSN: 0012-3692
- Author Web Link
- Cite
- Citations: 1
Bottier M, Delgado L, Shuttleworth MK, et al., 2022, Characterization of Ciliary Function in Bronchiectasis (EMBARC-BRIDGE Study), International Conference of the American-Thoracic-Society, Publisher: AMER THORACIC SOC, ISSN: 1073-449X
Shoemark A, Shteinberg M, De Soyza A, et al., 2022, Characterization of Eosinophilic Bronchiectasis A European Multicohort Study, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 205, Pages: 894-902, ISSN: 1073-449X
- Author Web Link
- Cite
- Citations: 20
Meldrum OW, Belchamber KBR, Chichirelo-Konstantynovych KD, et al., 2022, ERS International Congress 2021: highlights from the Respiratory Infections Assembly, ERJ OPEN RESEARCH, Vol: 8
Kumar K, Daley CL, Griffith DE, et al., 2022, Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments, EUROPEAN RESPIRATORY REVIEW, Vol: 31, ISSN: 0905-9180
- Author Web Link
- Cite
- Citations: 5
Kumar K, Loebinger MR, 2022, Nontuberculous Mycobacterial Pulmonary Disease: Clinical Epidemiologic Features, Risk Factors, and Diagnosis The Nontuberculous Mycobacterial Series, CHEST, Vol: 161, Pages: 637-646, ISSN: 0012-3692
- Author Web Link
- Cite
- Citations: 3
Aliberti S, Goeminne PC, O'Donnell AE, et al., 2022, Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations, LANCET RESPIRATORY MEDICINE, Vol: 10, Pages: 298-306, ISSN: 2213-2600
- Author Web Link
- Cite
- Citations: 34
Lipman M, Kunst H, Loebinger MR, et al., 2021, Non tuberculous mycobacteria pulmonary disease: patients and clinicians working together to improve the evidence base for care, INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, Vol: 113, Pages: S73-S77, ISSN: 1201-9712
- Author Web Link
- Cite
- Citations: 5
Adeloye D, Elneima O, Daines L, et al., 2021, The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease, LANCET RESPIRATORY MEDICINE, Vol: 9, Pages: 1467-1478, ISSN: 2213-2600
- Author Web Link
- Cite
- Citations: 42
Macfarlane L, Kumar K, Scoones T, et al., 2021, Diagnosis and management of non-cystic fibrosis bronchiectasis, CLINICAL MEDICINE, Vol: 21, Pages: E571-E577, ISSN: 1470-2118
- Author Web Link
- Cite
- Citations: 3
Housley GM, Peake S, Loebinger M, 2021, BREATHING PATTERN DYSFUNCTION IN PRIMARY CILIARY DYSKINESIA: MYTH OR REALITY?, Publisher: BMJ PUBLISHING GROUP, Pages: A130-A131, ISSN: 0040-6376
Mosgrove F, Haworth C, Loebinger M, et al., 2021, THE MICROBIOLOGY OF BRONCHIECTASIS EXACERBATIONS IN THE UK EMBARC REGISTRY AND IMPLICATIONS FOR PRESCRIBING IN PRIMARY CARE: A COHORT STUDY, Publisher: BMJ PUBLISHING GROUP, Pages: A41-A41, ISSN: 0040-6376
McLeese RH, Spinou A, Alfahl Z, et al., 2021, Psychometrics of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis, EUROPEAN RESPIRATORY JOURNAL, Vol: 58, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 7
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.